J&J Heats Up IL-23 Inflammatory Bowel Space With Tremfya Crohn's US Filing
Executive Summary
AbbVie's rival interleukin-23 drug Skyrizi is now approved in the US for both principal types of inflammatory bowel disease – ulcerative colitis and Crohn’s disease. Tremfya may not be too far behind.